FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

WHITTERS JOSEPH E
2. Issuer Name and Ticker or Trading Symbol

ACCURAY INC [ ARAY ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

1310 CHESAPEAKE TERRACE
3. Date of Earliest Transaction (MM/DD/YYYY)

9/4/2019
(Street)

SUNNYVALE, CA 94089
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/4/2019    P    12500  A $2.62 (1) 116780  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The purchase price represents the weighted average purchase price within a range of $1. Upon request by the Commission Staff, the Issuer or Security Holder, the Reporting Person will provide full information regarding the number of shares purchased at each separate price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
WHITTERS JOSEPH E
1310 CHESAPEAKE TERRACE
SUNNYVALE, CA 94089
X



Signatures
By: John McKune For: Joseph Whitters 9/6/2019
**Signature of Reporting Person Date


Accuray (NASDAQ:ARAY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Accuray Charts.
Accuray (NASDAQ:ARAY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Accuray Charts.

Accuray Inc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024
Thursday 25 April 2024 (6 days ago) • PR Newswire (US)
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Thursday 18 April 2024 (2 weeks ago) • PR Newswire (US)
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
Wednesday 17 April 2024 (2 weeks ago) • PR Newswire (US)
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
Tuesday 26 March 2024 (1 month ago) • PR Newswire (US)
Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Accuray Incorporated to Speak at 36th Annual Roth Conference
Monday 4 March 2024 (2 months ago) • PR Newswire (US)
Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Tuesday 27 February 2024 (2 months ago) • PR Newswire (US)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Tuesday 13 February 2024 (3 months ago) • Edgar (US Regulatory)
Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System
Tuesday 13 February 2024 (3 months ago) • PR Newswire (US)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Monday 12 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 7 February 2024 (3 months ago) • Edgar (US Regulatory)
Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Monday 5 February 2024 (3 months ago) • PR Newswire (US)